XON - Intrexon Corporation
| Previous Close | 6.39 |
| Open | 6.39 |
| Bid | 5.69 x 2900 |
| Ask | 0.00 x 2900 |
| Day's Range | 5.75 - 6.45 |
| 52 Week Range | 3.95 - 19.94 |
| Volume | 2,200,270 |
| Avg. Volume | 1,737,634 |
| Market Cap | 951.357M |
| Beta (3Y Monthly) | 2.04 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.50 |
| Earnings Date | Nov 6, 2019 - Nov 11, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.00 |
- PR Newswire
ActoBio Therapeutics™ Receives IND Green Light for New Antigen-Specific Immunotherapy Study Aimed at Improving Celiac Patients' Tolerance of Gluten
GHENT, Belgium, Aug. 19, 2019 /PRNewswire/ -- ActoBio Therapeutics, Inc., a wholly owned subsidiary of Intrexon Corporation (XON) and innovative clinical-stage biotechnology company focused on a new class of microbe-based therapeutic agents, announced that the U.S. Food and Drug Administration (FDA) has given its permission to an Investigational New Drug (IND) application for AG017, an innovative orally-delivered therapeutic candidate for the treatment of celiac disease. ActoBio Therapeutics™ is dedicated to developing and commercializing the next generation of oral antigen-specific immunotherapy utilizing its proprietary delivery vehicle.
- Simply Wall St.
Introducing Intrexon (NASDAQ:XON), The Stock That Tanked 77%
Intrexon Corporation (NASDAQ:XON) shareholders will doubtless be very grateful to see the share price up 46% in the...
- Thomson Reuters StreetEvents
Edited Transcript of XON earnings conference call or presentation 8-Aug-19 9:30pm GMT
Q2 2019 Intrexon Corp Earnings Call
Motley FoolIntrexon Corp (XON) Q2 2019 Earnings Call Transcript
XON earnings call for the period ending June 30, 2019.
- Zacks
Intrexon (XON) Reports Narrower-Than-Expected Loss in Q2
Intrexon (XON) posts a narrower-than-expected loss and misses sales estimates in the second quarter of 2019.
- PR Newswire
Intrexon Reports Second Quarter and First Half 2019 Financial Results
- Quarterly GAAP revenues of $36.0 million and net loss attributable to Intrexon of $38.8 million including non-cash charges of $8.0 million - GERMANTOWN, Md. , Aug. 8, 2019 /PRNewswire/ -- Intrexon Corporation ...
- PR Newswire
Precigen Announces First Patient Dosed in Phase 1 Study of PRGN-3005 UltraCAR-T™ in Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Milestone represents the first patient dosed with UltraCAR-T targeting solid tumors - First-in-class investigational therapy using autologous CAR-T cells targeting advanced, recurrent platinum resistant ...
- Zacks
Earnings Preview: Intrexon (XON) Q2 Earnings Expected to Decline
Intrexon (XON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- PR Newswire
Intrexon to Announce Second Quarter and First Half 2019 Financial Results on August 8th
GERMANTOWN, Md. , Aug. 1, 2019 /PRNewswire/ -- Intrexon Corporation (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, ...
- Motley Fool
Here's Why Intrexon Jumped 58% in June
The biotech is getting into the cannabinoids business.
- Simply Wall St.
What Does Intrexon Corporation's (NASDAQ:XON) Balance Sheet Tell Us About It?
Intrexon Corporation (NASDAQ:XON) is a small-cap stock with a market capitalization of US$1.2b. While investors...
- PR Newswire
ActoBio Therapeutics™ Progresses AG019 to Next Stage of a Phase Ib/IIa Clinical Study for the Treatment of Type 1 Diabetes
GHENT, Belgium, July 1, 2019 /PRNewswire/ -- ActoBio Therapeutics, Inc., a wholly owned subsidiary of Intrexon Corporation (XON) and innovative clinical-stage biotechnology company focused on a new class of microbe-based therapeutic agents, has announced that it will progress to the next stage of the Phase Ib/IIa clinical trial for investigational drug AG019 for the treatment of early-onset type 1 diabetes (T1D). This follows a scheduled review by the independent Data and Safety Monitoring Board, which supported moving forward with the study.
- PR Newswire
Precigen Announces First Patient Dosed in Phase 1/1b Study of PRGN-3006 UltraCAR-T™ in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or Higher Risk Myelodysplastic Syndrome (MDS)
GERMANTOWN, Md., June 26, 2019 /PRNewswire/ -- Precigen, Inc., a wholly-owned subsidiary of Intrexon Corporation (XON) and a biopharmaceutical company specializing in the development of innovative gene and cellular therapies to improve the lives of patients, today announced that the first patient has been dosed with PRGN-3006, a first-in-class investigational therapy using Precigen's non-viral UltraCAR-T™ therapeutic platform. PRGN-3006 UltraCAR-T is an autologous chimeric antigen receptor T (CAR-T) cell therapy under investigation for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) or higher risk myelodysplastic syndrome (MDS) (clinical trial identifier: NCT03927261).
- Zacks
Do Options Traders Know Something About Intrexon (XON) Stock We Don't?
Investors need to pay close attention to Intrexon (XON) stock based on the movements in the options market lately.
- Zacks
Intrexon Up on Striking 100M Cannabinoid Deal With Surterra
Intrexon (XON) inks a $100-million worth exclusive licensing deal with Surterra to produce cannabinoid in a reliable and cost-effective fashion, using its own yeast fermentation process. Shares climb.
- Motley Fool
Why Intrexon Stock Popped Today
A big deal with a medical cannabis company provided a spark for Intrexon.
- Benzinga
Intrexon Strikes $100M Partnership With Surterra For Cannabinoid Production
Intrexon Corporation (NASDAQ: XON) announced a 0 million partnership with Surterra Wellness to advance its cannabinoid production. The companies will join forces to push forward Surterra's cannabinoid production at a cost-effective, industrial scale utilizing Intrexon's proprietary yeast fermentation platform. Need more cannabis news?
- PR Newswire
Intrexon Corporation and Surterra Wellness Partner in $100mm Deal to Advance Commercial Scale Fermentation-based Cannabinoid Production
Exclusive Global Agreement to Transform Surterra's Ability to Produce Specific Cannabinoids to Meet Growing Demand, Boost Innovation and Product Development BUDAPEST, Hungary and ATLANTA , June 18, 2019 ...
- Markit
See what the IHS Markit Score report has to say about Intrexon Corp.
Intrexon Corp NASDAQ/NGS:XONView full report here! Summary * Bearish sentiment is high and has been increasing * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NegativeShort interest is high for XON with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting XON. Sentiment has worsened and traders added to their bearish short positions on June 14. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold XON had net inflows of $1.57 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- PR Newswire
Intrexon's Subsidiary Precigen to Present at the JMP Securities Life Sciences Conference
GERMANTOWN, Md. , June 13, 2019 /PRNewswire/ -- Intrexon Corporation (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, ...
- GuruFocus.com
Intrexon Corp (XON) CEO Randal J Kirk Bought $2.5 million of Shares
CEO of Intrexon Corp (NASDAQ:XON) Randal J Kirk bought 483,268 shares of XON on 06/07/2019 at an average price of $5.24 a share.
- GuruFocus.com
Weekly CEO Buys Highlight
Details the CEO buys this past week for the following companies: Capri Holdings, Odonate Therapeutics, Freeport-McMoRan, Intrexon and American Airlines
- Zacks
Intrexon (XON) Up 24.7% Since Last Earnings Report: Can It Continue?
Intrexon (XON) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
